Zydus

Ahmedabad, IndiaUnclaimed profile
19Medicines listed
0Certifications
0Facilities
0Export markets

Zydus Lifesciences Limited, formerly Cadila Healthcare, is a fully integrated global pharmaceutical company founded in 1952. It operates across formulations, active pharmaceutical ingredients, animal healthcare, and wellness products with FY-25 turnover of Rs. 23,200 crores.

Medicines & products

ARTE PLUS
Anti Malarials · tablet, dry syrup · 20/120 mg, 80/480 mg
Registered in 1 market
FALCIGO
Anti Malarials · injection, tablet · 50 mg, 60 mg, 120 mg
Registered in 1 market
MEFQUE
Anti Malarials · tablet · 250 mg
Registered in 1 market
LEVODAY
Anti-Infectives · tablet, infusion · 250 mg, 500 mg, 750 mg
Registered in 1 market
LINID
Anti-Infectives · tablet, infusion · 600 mg, 1200 mg
Registered in 1 market
OFLIN
Anti-Infectives · tablet, infusion · 100 mg, 200 mg, 400 mg, 800 mg
Registered in 1 market
ATEN
Cardiac · tablet · 25 mg, 50 mg, 75 mg, 100 mg
Registered in 1 market
ATEN AM
Cardiac · tablet · 25/5 mg, 50/5 mg
Registered in 1 market
DEPIN
Cardiac · capsule, tablet · 5 mg, 10 mg, 20 mg, 30 mg
Registered in 1 market
OCID
Gastro Intestinal · capsule, infusion · 10 mg, 20 mg, 40 mg
Registered in 1 market
110 of 19

Product list is informational, aggregated from public sources — availability is confirmed per-deal through verified offers, not public listings.

Documents & downloads

Know MorePDF · provided by ZydusExplorePDF · provided by ZydusZydus Therapeutics New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) granted Priority Review by the US FDAPDF · provided by ZydusZydus Lifesciences Financial Performance for Q4 & Full Year FY 26PDF · provided by ZydusPress Release – 19/05/2026PDF · provided by ZydusZydus and Assertio Holdings enter into an agreement for Zydus to acquire AssertioPDF · provided by ZydusZydus receives approval from DCGI to initiate Phase III trials of Zintrodiazine, a novel anti-malarial candidate.PDF · provided by ZydusZydus receives final approval from USFDA for Dapagliflozin Tablets, 5 mg and 10 mgPDF · provided by ZydusZydus Lifesciences Limited completes the acquisition of Agenus Inc.’s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.PDF · provided by ZydusSentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)PDF · provided by ZydusZydus launches Semaglutide Injection in an innovative, reusable multi-dose pen device in IndiaPDF · provided by ZydusZydus launches Aerolife Mini™, to simplify inhaler use for asthma and COPD patientsPDF · provided by ZydusESG Report 2021-22PDF · provided by ZydusESG Report 2022-23PDF · provided by ZydusESG Report FY-2023-24PDF · provided by ZydusESG Report FY-2024-25PDF · provided by ZydusBRSR FY23 Mapped with Global ESG FrameworksPDF · provided by ZydusPrivacy PolicyPDF · provided by Zydus

Capabilities

Dosage forms
CapsulesDry SyrupsGelsInfusionsInjectionsPatchesTablets
Therapeutic areas
Anti MalarialsAnti-InfectivesCardiacGastro IntestinalPain / Analgesics
Services
Active Pharmaceutical IngredientsAnimal Healthcare ProductsFormulationsWellness Products

Facility & product gallery

Sourcing from Zydus through PharmaGlobal

01Submit your requirement

Product, quantity, destination, and documents — in any of 23 languages.

02We review first

Every requirement passes a first-look review before any supplier exposure.

03Compare verified offers

Price, lead time, documents, and risk — side by side in a private deal room.

Data sources: Company disclosures. Last updated June 11, 2026. Profile data is aggregated from public regulatory registries and company disclosures. PharmaGlobal provides sourcing workflow tools; participants remain responsible for their own regulatory and trade compliance. Inaccurate? Report a correction.